Mr. Christopher Moreau reports

ALGERNON CLOSES SECOND TRANCHE OF PRIVATE PLACEMENT FINANCING

Algernon Health Inc. has closed the second tranche of its non-brokered private placement, previously announced on Nov. 6, 2025, with the first tranche closed on Nov. 14, 2025. Gross proceeds from the second tranche totalled $210,000 from the sale of three million units at an issue price of seven cents per unit.

The company did not pay any cash finders' fees pertaining to the second tranche of the offering.

The company will use the proceeds of the offering toward advancing its Alzheimer's disease (AD) program, including the opening of its first U.S. AD clinic, for general and administrative expenses, and for working capital purposes.

The securities issued and issuable, described in this and the previous news release on Nov. 6, 2025, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation.

About Algernon Health Inc.

Algernon Health is a Canadian health care company focused on the provision of brain optimized PET scanning services through a planned network of new clinics in North America for the early-stage detection of Alzheimer's disease, as well as other forms of dementia, epilepsy, neuro-ncology, and movement disorders. Algernon is also the parent company of a recently created private subsidiary, called Algernon USA LLC, that will oversee all U.S. neuroimaging operations.

We seek Safe Harbor.